Literature DB >> 35185285

Exosomal circ_PTPRA inhibits tumorigenesis and promotes radiosensitivity in colorectal cancer by enriching the level of SMAD4 via competitively binding to miR-671-5p.

Ying Yang1, Nengwen Yang2, Jun Jiang1.   

Abstract

Accumulating evidence supports that exosomal RNAs are crucial in tumor microenvironment and may be used as diagnostic biomarkers for cancers. This study aimed to determine the role of exosomal circular RNA_protein tyrosine phosphatase receptor type A (circ_PTPRA) in colorectal cancer (CRC). The morphology of exosomes was identified by transmission electron microscopy (TEM), and several exosome-specific proteins were quantified by western blot. The expression of circ_PTPRA, miR-671-5p and SMAD family member 4 (SMAD4) was detected using quantitative polymerase chain reaction (qPCR). Cell cycle was assessed using flow cytometry assay. Cell proliferation was assessed by MTT assay. Radiosensitivity was observed according to colony growth and cell apoptosis rate by colony formation assay and flow cytometry assay. The protein levels of proliferation- and apoptosis-related markers and SMAD4 were measured by western blot. The predicted relationship between miR-671-5p and circ_PTPRA or SMAD4 was verified by dual-luciferase reporter assay. Animal study was performed to investigate the role of exosomal circ_PTPRA in vivo. Circ_PTPRA expression was declined in serumal exosomes from CRC patients and CRC cell lines. Exosomal circ_PTPRA induced CRC cell cycle arrest and inhibited cell proliferation. Besides, exosomal circ_PTPRA promoted radiosensitivity of CRC cells, leading to inhibitory colony formation and increased apoptotic rate. In mechanism, circ_PTPRA functioned as a competing endogenous RNA (ceRNA) to increasing SMAD4 level by binding to miR-671-5p. Rescue experiments concluded that circ_PTPRA inhibited CRC growth and radioresistance by decreasing miR-671-5p expression, and miR-671-5p inhibition also inhibited CRC growth and radioresistance by enriching SMAD4 expression. Moreover, exosomal circ_PTPRA blocked tumor growth in vivo. Exosomal circ_PTPRA enhanced CRC cell radiosensitivity and inhibited CRC malignant development partially by regulating the miR-671-5p/SMAD4 pathway, hinting that exosomal circ_PTPRA might be used as a potential predicted and therapeutic target for CRC.
© The Author(s), under exclusive licence to Springer Nature B.V. 2021.

Entities:  

Keywords:  Colorectal cancer; Exosomes; SMAD4; circ_PTPRA; miR-671-5p

Year:  2022        PMID: 35185285      PMCID: PMC8817021          DOI: 10.1007/s10616-021-00506-y

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  29 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Global trends in colorectal cancer mortality: projections to the year 2035.

Authors:  Marzieh Araghi; Isabelle Soerjomataram; Mark Jenkins; James Brierley; Eva Morris; Freddie Bray; Melina Arnold
Journal:  Int J Cancer       Date:  2019-01-08       Impact factor: 7.396

Review 3.  Exosomes as Therapeutic Vehicles for Cancer.

Authors:  Whasun Lim; Han-Soo Kim
Journal:  Tissue Eng Regen Med       Date:  2019-04-23       Impact factor: 4.169

4.  miR-671-5p inhibits gastric cancer cell proliferation and promotes cell apoptosis by targeting URGCP.

Authors:  Tiefeng Qiu; Keping Wang; Xianwen Li; Jianhua Jin
Journal:  Exp Ther Med       Date:  2018-10-01       Impact factor: 2.447

Review 5.  Colorectal cancer.

Authors:  Ernst J Kuipers; William M Grady; David Lieberman; Thomas Seufferlein; Joseph J Sung; Petra G Boelens; Cornelis J H van de Velde; Toshiaki Watanabe
Journal:  Nat Rev Dis Primers       Date:  2015-11-05       Impact factor: 52.329

6.  Circular RNA circ_0001946 acts as a competing endogenous RNA to inhibit glioblastoma progression by modulating miR-671-5p and CDR1.

Authors:  Xinxing Li; Hongyu Diao
Journal:  J Cell Physiol       Date:  2019-01-21       Impact factor: 6.384

7.  Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme.

Authors:  Davide Barbagallo; Angelo Condorelli; Marco Ragusa; Loredana Salito; Mariangela Sammito; Barbara Banelli; Rosario Caltabiano; Giuseppe Barbagallo; Agata Zappalà; Rosalia Battaglia; Matilde Cirnigliaro; Salvatore Lanzafame; Enrico Vasquez; Rosalba Parenti; Federico Cicirata; Cinzia Di Pietro; Massimo Romani; Michele Purrello
Journal:  Oncotarget       Date:  2016-01-26

8.  Overexpression of miR-671-5p indicates a poor prognosis in colon cancer and accelerates proliferation, migration, and invasion of colon cancer cells.

Authors:  Wei Jin; Jinsheng Shi; Meiqin Liu
Journal:  Onco Targets Ther       Date:  2019-08-22       Impact factor: 4.147

9.  Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1.

Authors:  Xiaohong Hong; Na Liu; Yelin Liang; Qingmei He; Xiaojing Yang; Yuan Lei; Panpan Zhang; Yin Zhao; Shiwei He; Yaqin Wang; Junyan Li; Qian Li; Jun Ma; Yingqin Li
Journal:  Mol Cancer       Date:  2020-02-15       Impact factor: 27.401

10.  Comprehensive Analysis of a circRNA-miRNA-mRNA Network to Reveal Potential Inflammation-Related Targets for Gastric Adenocarcinoma.

Authors:  YunXia Liu; YeFeng Xu; Feng Xiao; JianFeng Zhang; YiQing Wang; YongWei Yao; JieWen Yang
Journal:  Mediators Inflamm       Date:  2020-08-01       Impact factor: 4.711

View more
  2 in total

1.  Exosome-Derived Non-Coding RNAs in the Tumor Microenvironment of Colorectal Cancer: Possible Functions, Mechanisms and Clinical Applications.

Authors:  Xian Chen; Mengmeng Jia; Jing Ji; Zhiying Zhao; Yanjie Zhao
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

2.  Integrated analysis of the functions and clinical implications of exosome circRNAs in colorectal cancer.

Authors:  Tianxiang Lei; Yongxin Zhang; Xiaofeng Wang; Wenwei Liu; Wei Feng; Wu Song
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.